NICE hits Keytruda with ‘no’ for urothelial cancer
The rejection comes after a review of new evidence collected while the blockbuster was available via the Cancer Drugs Fund.
Read More
Tag: blockbuster
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
